

State of theLife SciencesMarket ReportIT Services

# **Clinical Development Platforms Market Overview**

November 2020 : Complimentary Abstract / Table of Contents



#### Copyright © 2020 Everest Global, Inc.

We encourage you to share these materials internally within your company and its affiliates. In accordance with the license granted, however, sharing these materials outside of your organization in any form—electronic, written, or verbal—is prohibited unless you obtain the express, prior, and written consent of Everest Global, Inc. It is your organization's responsibility to maintain the confidentiality of these materials in accordance with your license of them.

### **Our research offerings for global services**

#### ▶ Market Vista™

Global services tracking across functions, sourcing models, locations, and service providers - industry tracking reports also available

# Application Services

- BPS | Banking & Financial Services
- BPS | Healthcare & Life Sciences
- ► BPS | Insurance
- ► Catalyst<sup>™</sup>
- Cloud & Infrastructure
- Customer Experience Management Services
- Contingent Workforce Management
- Data & Analytics
- Digital Services
- Engineering Services
- ► Enterprise Platform Services

# Finance & AccountingHuman Resources

- ITS | Banking & Financial Services
  ITS | Healthcare
- ITS | Insurance
- ► IT Services Executive Insights<sup>™</sup>
- ► ITS | Life Sciences
- ► Locations Insider™
- ▶ PricePoint<sup>™</sup>
- Procurement
- Recruitment Process Outsourcing
- Service Optimization Technologies

### More about membership

In addition to a suite of published research, a membership may include

- Accelerators<sup>™</sup>
- Analyst access
- Data cuts
- Pinnacle Model® reports
- PriceBook
- Virtual Roundtables
- Workshops

### **Custom research capabilities**

- Benchmarking | Pricing, delivery model, skill portfolio
- Peer analysis | Scope, sourcing models, locations
- Locations | Cost, skills, sustainability, portfolio plus a tracking tool
- Tracking services | Service providers, locations, risk
- Other | Market intelligence, service provider capabilities, technologies, contract assessment

### Membership information

- This report is included in the following research program(s)
  - Life Sciences IT Services (ITS)
- If you want to learn whether your organization has a membership agreement or request information on pricing and membership options, please contact us at **info@everestgrp.com**

# Contents

For more information on this and other research published by Everest Group, please contact us:

Nitish Mittal, Vice President


Chunky Satija, Practice Director

Nisarg Shah, Senior Analyst


1.	Introduction and overview	5
	Research methodology	6
	Key information on the report	7
	Background and/or introduction	8
	Focus of the research	9
2.	Clinical development platforms supply ecosystem and outlook	10
	Global clinical trials technology market overview	11
	Clinical technology supply landscape	12
	Clinical technology IT market size	13
	Clinical technology IT market size by geography	14
3.	The end-to-end platform story	15
	Challenges with the current clinical product landscape	16
	Buyers' expectations from clinical trial products	17
	Everest Group's view of an end-to-end clinical development platform	19
	Primary insights from buyers on the end-to-end platform market	20
	Challenges to adoption of end-to-end platforms	22
	Implications for clinical development platform vendors	23
4.	Future business cases for end-to-end platforms	24
	Accelerating patient-centric investments for virtual trials	26
	<ul> <li>Enabling adoption of adaptive trials to speed trial timelines</li> </ul>	30

# Contents

5.	<ul> <li>Advanced analytics and AI investments for improved clinical decision making</li> </ul>	33
	Automation for reducing manual intervention in pharmacovigilance	37
	Appendix	39
	• Glossary	40
	Research calendar	41



# This report is based on four key sources of proprietary information



Assessments for Bioclinica, Bio-Optronics, Castor, CliniOps, Covance, Datatrak, eClinicalHealth, Ennov, IBM, Navitas Life Sciences, Parexel, PRA Health Sciences, and Veeva Systems excludes product vendor inputs and are based on Everest Group's proprietary Transaction Intelligence (TI) database, product vendor public disclosures, and Everest Group's interactions with pharmaceutical firms that are buyers of clinical development platforms or products The source of all content is Everest Group unless otherwise specified

Confidentiality: Everest Group takes its confidentiality pledge very seriously. Any information we collect that is contract specific will only be presented back to the industry in an aggregated fashion



# **Background of the research**

The rising cost of drug development, coupled with increasing regulatory pressures, has led life sciences organizations to rethink the way clinical trials are being conducted – the focus is increasingly more on failing fast and failing cheap. However, clinical trial challenges, such as siloed data management, delayed timelines due to patient recruitment concerns, and a complex environment of multiple technology solutions, aggravate a pharma organization's woes further. Digital technologies and products have been deployed across the clinical trial landscape to solve for these challenges and bring in efficiencies and automation to reduce manual errors in the process.

Recently, product vendors have started integrating these siloed point solutions into an integrated, modular, and interoperable end-to-end clinical development platform – one platform to address the pharma organization's needs, right from study start-up to regulatory and safety affairs. The benefits of a single-platform estate that are claimed are efficient data management, reduced total cost of ownership, and improved visibility of operations. Pharma executives, however, are yet to be convinced about a unified platform approach as they look for success stories and business casing to really move the needle from a best-of-breed approach to a consolidated approach. Everest Group's Clinical Development Platforms – Products PEAK Matrix<sup>®</sup> Assessment 2020 looks at the current vendor landscape offering such platforms and presents the executive sentiment and insights for such platforms.

This report looks at:

- Clinical trial products market size
- Everest Group view of a unified clinical development platform landscape
- Enterprise view of unified clinical development platforms and challenges to adoption of such platforms

Scope of this report:





Industry Life sciences (biopharmaceuticals, medical devices, and Contract Research Organizations (CROs))



Vendor offering Clinical development platforms



## **Scope of the research**


In this report, Everest Group focuses on the clinical & pre-clinical trials phase of the life sciences value chain



Building blocks of clinical deve	Building blocks of clinical development systems (Not exhaustive)				
Electronic Data Capture (EDC)	Clinical Trial Management Systems (CTMS)	Randomization and Trial Supply Management (RTSM)	Clinical Data Management (CDM)		
Regulatory systems	Electronic Patient Reported Outcomes (ePRO)	Pharmacovigilance (PV)	Risk-based Monitoring (RBM)		



# The Clinical Development Platforms – State of the Market report provides a deep dive into the clinical development platforms market; the exhibits below illustrate the depth of the report



### **Research calendar** Life sciences IT services

Published Planned Current release

Flagship Life Sciences IT services reports	Release date
Life Sciences Sales and Marketing Data & Analytics Services PEAK Matrix® Assessment 2020	December 2019
Life Sciences State of the Market Report – Trends, Service Provider Performance in 2019, and Outlook for 2020	February 2020
Medical Devices Digital Services PEAK Matrix <sup>®</sup> Assessment 2020	June 2020
Life Sciences Medical Devices Digital Services – State of the Market Report	July 2020
Life Sciences Medical Devices Digital Services – Service Provider Profiles Compendium	July 2020
Clinical Development Platforms – Vendor Landscape with Products PEAK Matrix® Assessment 2020	September 2020
Clinical Development Platforms – Vendor Provider Profiles Compendium	October 2020
Clinical Development Platforms Market Overview	November 2020
Life Sciences Digital Services PEAK Matrix® Assessment 2021	November 2020
Life Sciences Digital Services – Service Provider Profiles Compendium	December 2020

Thematic Life Sciences IT services reports	Release date
Effective Value-Based Contracting in Life Sciences	February 2020
Regulatory Overhaul of the EU Medical Device Market	April 2020
Future Readiness of Life Sciences Enterprise Supply Chains	June 2020
Insourcing in Life Sciences – The Quest for Talent Supremacy	Q4 2020
Intelligent Manufacturing for Life Sciences Enterprises	Q4 2020

#### For a list of all of our published Life Sciences IT reports, please refer to our website page Note:





Everest Group is a consulting and research firm focused on strategic IT, business services, engineering services, and sourcing. Our clients include leading global enterprises, service providers, and investors. Through our research-informed insights and deep experience, we guide clients in their journeys to achieve heightened operational and financial performance, accelerated value delivery, and high-impact business outcomes. Details and in-depth content are available at **everestgrp.com**.

### **Stay connected**

Website everestgrp.com

Social Media

₩ @EverestGroup

in @Everest Group

- @Everest Group
- @Everest Group

Blog everestgrp.com/blog

Podcast DigitalRealI**T**y

🔞 Listen on Apple Podcasts 🛛 🍃 Google P

Dallas (Headquarters) info@everestgrp.com +1-214-451-3000

Bangalore india@everestgrp.com +91-80-61463500

Delhi india@everestgrp.com +91-124-496-1000 London unitedkingdom@everestgrp.com +44-207-129-1318

New York info@everestgrp.com +1-646-805-4000

Toronto canada@everestgrp.com +1-416-388-6765

This document is for informational purposes only, and it is being provided "as is" and "as available" without any warranty of any kind, including any warranties of completeness, adequacy, or fitness for a particular purpose. Everest Group is not a legal or investment adviser; the contents of this document should not be construed as legal, tax, or investment advice. This document should not be used as a substitute for consultation with professional advisors, and Everest Group disclaims liability for any actions or decisions not to act that are taken as a result of any material in this publication.